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Dear Editor, 
 
Ocrelizumab is a recombinant humanized monoclonal antibody approved for the treatment of 
multiple sclerosis (MS) directed against CD20, a membrane glycosylated protein expressed on B-
lymphocytes, but not plasma cells or neutrophils. Ocrelizumab structure and me- chanism of action 
are related to rituximab, which has been used for years in the treatment of rheumatoid arthritis. The 
precise mechanisms through which ocrelizumab exerts its therapeutic clinical effects are not fully 
elucidated but, likely, CD20 binding leads to antibody-dependent cellular cytolysis and complement-
mediated lysis of CD20 expressing cells [1]. 
In January 2018, ocrelizumab has been approved in Europe for the treatment of both relapsing 
remitting (RRMS) and primary progressive MS (PPMS) and it is administered intravenously 
every six months. Infusion reactions, infections and a small proportion of malignancies are the 
main side effects that have been reported in clinical trials [2]. 
We describe a case of absolute neutropenia in a naïve patient af- fected by RRMS treated with 
ocrelizumab. 
A 26-year old naïve woman was diagnosed with RRMS in August 
2018 and started ocrelizumab 600 mg, administered as two separate infusions over a period of two 
weeks, on October 2018. She had no other medical illness and did not take any concomitant 
medications. 
She received her third cycle of ocrelizumab, the first as a single 600 mg infusion, on April 15th 
2019. Pre-infusion biochemical analysis, immunoglobulin A (IgA), G (IgG), M (IgM) and blood 
counts were normal and she did not experience any infections prior to the infusion. 
On July 30th 2019 she reported pain in her mouth, headache and fever with chills evolving over a 
2-day period and presented to the Emergency Room (ER) on August 1st 2019 for transient loss of 
con- sciousness. On physical examination, she had aphthous stomatitis on tongue and pharynx and a 
normal neurologic examination except for mild lethargy. She had no evidence of organomegaly or 
skin rash. 
On August 1st, body temperature was 39 °C, white blood cell count, absolute lymphocyte count 
(ALC), absolute neutrophil count (ANC) and absolute monocyte count (AMC) were 1.1 × 109/L 
(normal range 4.0–10.0 × 109/L),   0.3 × 109/L   (normal   range   1.5–3.5 × 109/L), 
0 × 109/L (normal range 2.0–6.0 × 109/L), and 0.8 × 109/L (normal range 0.1–0.9 × 109/L), 
respectively. C-reactive protein (CRP) and procalcitonin (PCT) were 36 U/L (normal value < 5 
U/L) and 1.0 U/L (normal value < 0.5 U/L). Red blood cell count was within the normal range. 
Full blood examinations are summarized in Table 1. 
In the ER, an otorhinolaryngology evaluation was performed and it demonstrated aphthous 
lesions on left margin of the tongue and epi- glottis and white spots on palatine tonsils. Brain 
computed tomography and investigations for infections as chest x-ray, abdominal ultrasounds, 
cultures of blood and urine were negative. Considering the presence of headache, high body 
temperature and lethargy, she subsequently un- derwent a lumbar puncture: physical-chemical 
analysis of cerebrospinal fluid was normal and molecular tests for viruses, including Epstein Barr 
Virus, Cytomegalovirus, Human Herpes Simplex 1 and 2 and Varicella- zoster virus, were negative. 
She was hospitalized and empirically treated with acyclovir at the dosage of 10 mg/kg three 
times a day and ceftriaxone 2 g/day, in- travenously, starting from August  1st 2019. Symptoms  
started im- proving two days after treatment started and ANC, ALC and CRP re- turned to normal. 
She was discharged on August 6th 2019: headache and fever were completely resolved and patient 
displayed exclusively a mild stomatitis. Blood tests performed 14 days after discharge were normal 
(Table 1). 
Late-onset neutropenia (LON) is defined as an ANC of < 1.5 × 109/L that develops > 4 weeks after 
last drug administration, preceded by a normal neutrophil count, without other identifiable causes. 
LON has emerged as a possible adverse event of rituximab treatment and its incidence, as calculated 
from various studies, ranges from 3% to 27% [3]. Causes of LON following rituximab are poorly 
understood and many mechanisms such as infectious etiology, antibody-mediated de- structions, 
neutrophil apoptosis triggered by the FAS/FAS ligand pathway, low granulocytic progenitor cell 
reserve and abnormal loca- lization of immature precursors in the bone marrow have been postu- 
lated  [3]. 
Clinical issues following LON, including infectious risk and ritux- imab re-treatment, are of 
outstanding importance as they may affect treatment strategy and final patient outcome. Individual 
rates of in- fections in literature range from 0 to 20% and they usually are mild and self-limited  [4].  
The  use  of  granulocyte  colony-stimulating  factor, filgrastim, seems to minimally affect the course 
of LON, speeding rather than altering LON resolution [3]. 
In the RRMS clinical trial, neutropenia was found in 14.7% of ocrelizumab patients, 
compared to 40.9% of interferon beta-1a pa- tients. In the PPMS trial, neutropenia occurred in 13% 
of ocrelizumab- treated patients compared to 10% in placebo. The majority of decreased neutrophil 
counts were transient and ANC were between 1.5 × 109/L and 1.0 × 109/L. Only 1% of patients 
displayed an ANC < 1.0 × 109/ L and none of those cases was associated with infections. Only 
two patients who respectively displayed 0.5 < ANC < 1.0 × 109/L and ANC < 0.5 × 109/L 
needed a specific treatment with filgrastim. All of those patients continued with ocrelizumab 
treatment after neutropenia resolved [2]. 
Some insight about continuation of ocrelizumab treatment after LON could be driven by 
rheumatologic literature. Wolach et al. re- ported that re-challenging a patient with rituximab 
following LON could lead to recurrent episodes [3]. On the contrary, Monaco et al. described a case 
series of patients with rheumatic disease who devel- oped LON following rituximab administration 
and stated that rituximab re-treatment after recovery from LON appears safe. Specifically, authors 
described 25 patients who were re-treated with rituximab with only two reported cases of LON, who 
experienced complete recovery without adverse events while neutropenic [5]. Overall, taking into 
account the possibility of recurrence of LON and the unclear implications of re- treatment, it seems 
reasonable to evaluate whether to administer fur- ther doses of ocrelizumab on a case-by-case basis. 
Currently, available data are insufficient to establish guidance for timing of blood count 
monitoring. One of the difficulties in character- izing LON is that very diverse and heterogeneous 
populations have been assessed in most studies. Rissanen et al., who described a case of ab- solute 
neutropenia after rituximab treatment in a multiple sclerosis patient, suggest monitoring of white 
blood cell count during the first five months following rituximab administration, as this is when the 
risk is expected to be the highest [6]. Dunleavy et al., who reported a case series of  153 patients  
treated  with  rituximab  for  B-cell lymphoma, mantle cell lymphoma and Burkitt lymphoma, 
suggest evaluation of complete blood cell count every three months for the first year [7]. 
There is only one reported case of LON developing 73 days after ocrelizumab infusion in an MS 
patient, who was previously treated with glatiramer acetate, interferon-β-1a and dimethyl fumarate 
[8]. Patient developed fever, mild lethargy and mucositis and her ANC and ALC were 0.0 and 0.3 × 
109/L, respectively. She was treated with cefepime and acyclovir and she was given a single dose of 
filgrastim 300 μg and methylprednisolone 1000 mg with net improvement of both ANC and ALC, 
which returned to normal values. 
In our case, absolute neutropenia could be directly correlated with ocrelizumab action, likely 
through an immune-mediated mechanism that could resemble the one involved in rituximab LON, 
or, alter- natively, could be a consequence of a viral infection such as Human Herpes Virus, which 
we were not able to detect. 
Overall, this case highlights the importance of serial monitoring of blood count after 
ocrelizumab, raises questions regarding the con- tinuation of ocrelizumab use, and prompts 
further investigations in order to unravel underneath causes. 
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